The news story you are looking for has expired. A more recent related article is displayed below.

Sponsored Links

Repros Therapeutics to raise $1 million in financing

Sep 09, 2009 (Datamonitor via COMTEX) --

Company: Repros Therapeutics Inc (RPRX)

Repros Therapeutics, a developer of oral small molecule drugs, has entered into a definitive agreement with a single institutional investor to sell 1.5 million shares of its common stock at $0.65 per share for gross proceeds of approximately $1 million.

This financing will allow Repros to continue its business activity for the near term and provide it with more flexibility to continue exploring various strategic alternatives.

The offering is expected to close on or about September 11, 2009, subject to the satisfaction of customary closing conditions. 

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Copyright (C) 2009 Datamonitor. All rights reserved

News Provided by COMTEX

Company: Repros Therapeutics Inc (RPRX)


Related terms: business, drugs

Related Articles

Repros Therapeutics to raise $4.4 million in financing - Zibb.com
Oct 12, 2009
Repros Therapeutics to raise...million in financing Repros Therapeutics has entered...shares of its common stock at $1...million. Repros Therapeutics focuses on...oral small molecule drugs for major...

CF sweetens bid for US rival Terra with $3.2bn cash
Nov 2, 2009
...cash and 0.1034 of a share of CF common stock for each Terra share. The offer...30 October closing price for CF common stock, CF said. CF calculated the...said is not subject to either a financing condition or the approval of CF...

A Three-Way Strategy on Repros Therapeutics
Oct 26, 2009
...activity surged in Repros Therapeutics (RPRX) on Friday...Way Strategy on Repros Therapeutics Oct 26, 2009 ...Biotech as Public Financing Takes a Breather...Way Strategy on Repros Therapeutics Oct 26, 2009...

Journal Communications Reports Third Quarter 2009 Results
Oct 21, 2009
...earnings per share of class A and B common stock were $0.02 for both. Excluding...earnings per share of class A and B common stock were $0.08 for both. This compared...earnings per share of class A and B common stock were $0.16 for both. EBITDA...